Biogen Inc.’s decision to cut the price of its Alzheimer’s drug Aduhelm in half starting Jan. 1 is “a day late and a dollar short,” according to Raymond James, which is not expecting the move to change the trajectory of the drug launch or restore Biogen’s battered reputation.
Biogen Inc.’s decision to cut the price of its Alzheimer’s drug Aduhelm in half starting Jan. 1 is “a day late and a dollar short,” according to Raymond James, which is not expecting the move to change the trajectory of the drug launch or restore Biogen’s battered reputation.